Population Genetics & Evolution of Antibiotic Resistance

群体遗传学

• 批准号: 7059909
• 负责人: Bruce Richard Levin
• 金额: $ 18.68万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-01 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7059909
• 关键词: Escherichia coli; antibiotics; bacterial genetics; biochemical evolution; computer simulation; dosage; drug resistance; environmental adaptation; gene expression; gene mutation; laboratory mouse; mathematical model; microorganism population study; model design /development; natural selections; nucleic acid sequence; population genetics; rifamycins; statistics /biometry; streptomycin

DESCRIPTION (provided by applicant): Acquired antibiotic resistance is that which evolves in populations of susceptible commensal and pathogenic bacteria colonizing and infecting hosts that are under antibiotic treatment or prophylaxis. Acquired antibiotic resistance can result in treatment failure and contribute to transmissible or primary antibiotic resistance. The research proposed in this application will be devoted to understanding, in a quantitative and predictive way, the genetic, bacterial, host factors and population dynamic processes responsible for the evolution of acquired resistance in populations of bacteria infecting uncompromised mammals treated with single and multiple antibiotics. Towards this end, we will develop and analyze the properties of mathematical and computer simulation models of the within-host population dynamics of antibiotic treatment and the evolution of resistance and perform in vitro and in vivo (laboratory mouse) experiments with a capsulated E. coli (018:K1 :H7). In these experiments, we will estimate the parameters of these models, evaluate the reality of the assumptions behind their construction and test the validity of the predictions made from the analysis of their properties. The goals of this investigation are to; (1) Elucidate the conditions (dosage levels and treatment regimes) under which selection will favor the evolution of resistance in uncompromised mammals infected with antibiotic susceptible bacteria and treated with single antibiotics, multiple antibiotics and antibiotics for which clinical resistance requires multiple mutations. (2) Evaluate the contribution of post antibiotic effects (delays in the resumption of normal growth of antibiotic exposed bacteria after antibiotics are no longer at inhibitory concentrations) to the evolution of acquired resistance in populations of bacteria infecting antibiotic treated mammals. (3) Determine the contribution of elevated mutation rates to evolution acquired antibiotic resistance and the conditions under which antibiotic-mediated selection will result in the evolution of genes that augment mutation rates, mutator genes. The proposed research directed at these goals is in part, motivated by an academic interest in the mechanisms of adaptive evolution in bacteria. This research is also motivated by its direct utility to the health sciences and, in particular, to facilitate the design and evaluation of clinically effective antibiotic treatment protocols that minimize the likelihood of acquired antibiotic resistance evolving in the target population of bacteria.

描述（由申请人提供）：获得性抗生素耐药性是在接受抗生素治疗或预防的宿主定植和感染的易感共生菌和病原菌群体中进化而来的。获得性抗生素耐药性可能导致治疗失败，并导致传染性或原发性抗生素耐药性。本申请中提出的研究将致力于以定量和预测的方式了解遗传、细菌、宿主因素和群体动态过程，这些过程负责感染用单一和多种抗生素治疗的未受感染的哺乳动物的细菌群体中获得性耐药性的进化。为此，我们将开发和分析抗生素治疗的宿主群体动态和耐药性进化的数学和计算机模拟模型的特性，并使用胶囊化大肠杆菌（018：K1：H7）进行体外和体内（实验室小鼠）实验。在这些实验中，我们将估计这些模型的参数，评估其构建背后的假设的现实性，并测试通过分析其属性而做出的预测的有效性。这项调查的目标是： (1) 阐明在何种条件（剂量水平和治疗方案）下，选择将有利于感染抗生素敏感细菌并用单一抗生素、多种抗生素和临床耐药性需要多重突变的抗生素治疗的未受影响的哺乳动物中耐药性的进化。 (2) 评估抗生素后效应（抗生素不再处于抑制浓度后，接触抗生素的细菌恢复正常生长的延迟）对感染抗生素治疗的哺乳动物的细菌群体获得性耐药性进化的贡献。 (3) 确定突变率升高对获得性抗生素抗性进化的贡献，以及抗生素介导的选择将导致增加突变率的基因（增变基因）进化的条件。针对这些目标的拟议研究部分是出于对细菌适应性进化机制的学术兴趣。这项研究的动机还在于其对健康科学的直接效用，特别是促进临床有效的抗生素治疗方案的设计和评估，以最大限度地减少目标细菌群体中获得性抗生素耐药性的可能性。